| ID | Name | CAS | Properties |
logPoct/wat |
| 32-132-9 |
Isonipecotic acid, N-(2,4,5-trifluoro-3-methoxybenzoyl)-, octyl ester
|
|
3 | 4.868 |
| 32-182-4 |
4-Cyclopropanecarbonyl-3,5-bis(trimethylsilanyloxy)cyclohexa-2,5-diene-carboxylic acid, ethyl ester
|
|
3 | 4.245 |
| 32-242-7 |
2,4,6(1H,3h,5h)-pyrimidinetrione, 5-phenyl-1-(phenylmethyl)-
|
|
3 | 2.049 |
| 32-318-3 |
Isonipecotic acid, N-(2,4,5-trifluoro-3-methoxybenzoyl)-, isobutyl ester
|
|
3 | 3.164 |
| 32-527-1 |
5«alpha»-Androstane-3«alpha»,17«beta»-diol, bis(trimethylsilyl) ether
|
10426-36-5 |
3 | 7.469 |
| 32-570-3 |
Phosphorothioic acid, S-[2-[(1-cyano-1-methylethyl)amino]-2-oxoethyl] O,O-diethyl ester
|
3734-95-0 |
3 | 2.319 |
| 32-611-7 |
Prosta-5,11-dien-1-oic acid, 9-oxo-11,15-bis[(trimethylsilyl)oxy]-, trimethylsilyl ester, (5Z,11«alpha»,13E,15S)-
|
39003-20-8 |
3 | 8.263 |
| 32-772-9 |
7H-imidazo[4,5-d]-v-triazin-4-ol, 7-butyl-, (keto form)
|
|
3 | -0.167 |
| 32-797-2 |
N-(5,6-Dichloro-1,3-benzothiazol-2-yl)-2,2,3,3,3-pentafluoropropanamide
|
|
3 | 4.739 |
| 32-817-9 |
5,5-Diethyl-2-methyl-4-acetyl-1,3,4-oxadiazoline
|
|
3 | 1.715 |
| 33-526-1 |
1-[[(1S)-2,3,4,6,7,8,9,9a-Octahydro-1H-quinolizin-1-yl]methyl]pyrrolidine-2,5-dione
|
|
3 | 1.400 |
| 33-821-3 |
Androst-5-ene-3«beta»,17«beta»-diol-16-one, TMS
|
|
3 | 8.694 |
| 33-888-0 |
Phosphoric acid, 7-chlorobicyclo[3.2.0]hepta-2,6-dien-6-yl dimethyl ester
|
23560-59-0 |
3 | 3.060 |
| 33-942-9 |
2,6-Pyridinedicarboxylic acid, 2-methylhex-3-yl 2-methylpentyl ester
|
|
3 | 4.656 |
| 34-074-2 |
4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro, 3-methyl
|
|
3 | 0.888 |
| 34-097-7 |
Isonipecotinoylisonipecotic acid, N'-(2,5-di(trifluoromethyl)benzoyl)-, propyl ester
|
|
3 | 4.768 |
| 34-142-6 |
4,4'-Bis(2-amino-1-naphthylazo)-2,2'-stilbene disulfonic acid
|
5437-12-7 |
3 | 8.652 |
| 34-583-7 |
Isonipecotic acid, N-(2,6-difluoro-3-methylbenzoyl)-, hexyl ester
|
|
3 | 4.249 |
| 34-606-1 |
N-(2,2,3,3,4,4,4-Heptafluorobutanoyl)-N-(4-methoxy-1,3-benzothiazol-2-yl)-2,2,3,3,4,4,4-heptafluorobutanamide
|
|
3 | 5.830 |
| 34-609-8 |
4H-Pyrido[1,2-a]pyrimidin-4-one, 7-methyl
|
|
3 | 1.003 |
| 34-872-6 |
Methyl 5-«beta»-cholan-3-«beta»-ol-12-one-24-oate, oxime, TMS
|
|
3 | 8.272 |
| 35-400-8 |
5«beta»-Campestanol (24«alpha»-methyl-5«beta»-cholestan-3«beta»-ol), TMS
|
|
3 | 9.574 |
| 35-412-5 |
1,3,2-Diazaphosphol-4-ene, 2,4-dichloro-1,3-dicyclohexyl-
|
|
3 | 5.773 |
| 35-572-8 |
1,3,5,2,4,6-Triazatriphosphorine, 2,2,4,4,6,6-hexabromo-2,2,4,4,6,6-hexahydro-
|
13701-85-4 |
3 | 8.208 |
| 35-819-4 |
5-methylaceto-5'-(3-buten-1-ynil)-2,2'-bithienyl
|
|
3 | 4.146 |
| 35-938-2 |
5«alpha»-Pregnane-3«beta», 20«beta», 21-triol, MO TMS
|
|
3 | 8.937 |
| 36-159-6 |
Isonipecotic acid, N-(2,4,5-trifluoro-3-methoxybenzoyl)-, decyl ester
|
|
3 | 5.649 |
| 36-250-4 |
epi-5«beta»-Campestanol (24«alpha»-methyl-5«beta»-cholestan-3«alpha»-ol), TMS
|
|
3 | 9.574 |
| 36-417-9 |
O-Ethyl-O-(1,1-difluoro-2-bromoethyl)-N-(1-methylpropyl)-phosphorothioamidate
|
|
3 | 3.640 |
| 36-761-7 |
5-Pregnen-3-«alpha»,20-«alpha»-diol-20-GlcNAc TMS
|
|
3 | 9.712 |
| 36-920-0 |
2,5,5-Trimethyl-4-propionyl-1,3,4-oxadiazoline
|
|
3 | 1.325 |
| 36-921-9 |
2-Pyrrolidinone, 1-ethyl-4-[2-(4-morpholinyl)ethyl]-3,3-diphenyl-
|
309-29-5 |
3 | 3.173 |
| 37-009-1 |
3«alpha»,7«alpha»-dihydroxy-5«beta»-C27-bile acid, methyl ester, TMS
|
|
3 | 9.311 |
| 37-178-4 |
1,3-Dimethyl-5-(3-hydroxycyclohexen-1-yl)hexahydropyrimidine-2,4,6-trione
|
|
3 | 0.124 |
| 37-265-7 |
allo-Cholanic acid, 3«alpha»,7«alpha»,12«alpha»-trihydroxy, Me-DMES
|
|
3 | 10.285 |
| 37-313-3 |
1,5,6-Triazabicyclo[3.1.0]hexane, 4-methyl-2,2,6-tris(trifluoromethyl)-4-phenyl-
|
|
3 | 4.554 |
| 37-388-1 |
4-Cyclopropyl-6-methyl-N-acetyl-N-phenylpyrimidin-2-amine
|
|
3 | 3.347 |
| 37-448-4 |
1-«beta»,3-«alpha»,12-«alpha»-Trihydroxy-5-«beta»-cholanoic acid, MeTMS
|
|
3 | 9.115 |
| 37-683-3 |
5-«beta»-Pregnan-3-«alpha»-ol-20-one, MO-TMS
|
|
3 | 6.888 |
| 37-942-5 |
Isonipecotic acid, N-(2,5-di(trifluoromethyl)benzoyl)-, pentadecyl ester
|
|
3 | 9.211 |
| 38-104-4 |
2-(N-Ethyl-N-m-tolyl)aminoethanol, (3-cyanopropyl)dimethylsilyl ether
|
|
3 | 4.347 |
| 38-108-0 |
D-Tryptophan, N(O,S)-ethoxycarbonyl, (S)-(+)-3-methyl-2-butyl ester
|
|
3 | 3.891 |
| 38-174-7 |
4,5,6,7-Tetrahydropyrazolo[1,5-d][1,2,4]-triazin-4-one, 2,6-dimethyl-7,7-tetramethylene
|
|
3 | 0.684 |
| 38-214-2 |
Isonipecotic acid, N-(2,4,5-trifluoro-3-methoxybenzoyl)-, undecyl ester
|
|
3 | 6.039 |
| 38-420-3 |
Silane, [(3,7,11,15-tetramethyl-2-hexadecenyl)oxy]trimethyl-
|
57397-39-4 |
3 | 8.223 |
| 38-562-6 |
Androstane, 3,17-bis[(trimethylsilyl)oxy]-, (3«alpha»,5«alpha»,17«alpha»)-
|
10426-35-4 |
3 | 7.469 |
| 38-659-9 |
O-Ethyl-O-(1,1-difluoro-2-chloroethyl)-N-propyl-phosphorothioamidate
|
|
3 | 3.095 |
| 38-787-7 |
1H,5H,7H,11H-Dipyrazolo[1,2-a:1',2'-d][1,2,4,5]tetrazine, tetrahydro-
|
37882-92-1 |
3 | -0.240 |
| 38-861-4 |
5-«alpha»-Pregnan-3-«beta»-16-«alpha»-diol-20-one, TMS
|
|
3 | 7.284 |
| 39-046-8 |
3-(4-Anilino-1-naphthylazo)-2,7-naphthalene disulfonic acid
|
57322-42-6 |
3 | 6.645 |
| 39-307-8 |
15,16-Epoxylabda-13(16),14-dien-8 .alpha.-ol
|
|
3 | 5.206 |
| 39-432-9 |
Isonipecotinoylisonipecotic acid, N'-(2,5-di(trifluoromethyl)benzoyl)-, ethyl ester
|
|
3 | 4.378 |
| 39-634-5 |
5-«alpha»-Pregnan-20-«beta»-ol-3-one, MO-TMS
|
|
3 | 6.888 |
| 39-730-8 |
5-«beta»-Pregnan-20-«beta»-ol-3-one, MO-TMS
|
|
3 | 6.888 |
| 39-949-6 |
2,4-Imidazolidinedione, 5,5-diphenyl-1,3-bis(trimethylsilyl)-
|
|
3 | 4.864 |
| 39-983-8 |
4-Quinolinol,4-ethenyl-1-ethyldecahydro-2-methyl-(2«alpha»,4«beta»,4a«alpha»,8a«beta»)
|
38463-58-0 |
3 | 2.576 |
| 40-056-5 |
6H-Pyrido[2,1-b]quinazolin-6-one, 7,8,9,10-tetrahydro- 9-methyl
|
|
3 | 1.819 |
| 40-738-8 |
1,3-Bis(2-phenyl-1,3,4-oxadiazol-5-yl)perfluoropropane
|
5086-79-3 |
3 | 5.306 |
| 40-865-7 |
Pyrazolo[1,5-d][1,2,4]triazin-3-one, 2,5,6-trimethyl-7,7-tetramethylene
|
|
3 | 1.151 |
| 41-014-0 |
Isonipecotic acid, N-(2,4,5-trifluoro-3-methoxybenzoyl)-, propyl ester
|
|
3 | 2.918 |
| 41-243-6 |
myo-Inositol 3,4,5,6-tetraacetate, bis(trimethylsilyl) ether
|
|
3 | 2.167 |
| 41-301-1 |
Isonipecotic acid, N-(2,6-difluoro-3-methylbenzoyl)-, tridecyl ester
|
|
3 | 6.980 |
| 41-340-8 |
1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl-
|
|
3 | 3.238 |
| 41-410-0 |
allo-Cholanic acid, 3«beta»,7«beta»,12«beta»-trihydroxy, Me-TMS
|
|
3 | 9.115 |
| 41-507-3 |
2-(2,6-Dioxo-3-piperidyl)isoindoline-1,3-dione, N-trimethylsilyl-
|
|
3 | 1.635 |
| 41-554-1 |
1-Methyl-9-[(1e)-1-propenyl]-1,9-dihydro-6h-purin-6-one
|
|
3 | 0.621 |
| 41-600-9 |
2,3,4,5,7,8,9,10,11,12-Decahydro-1H-5a,13-diaza-cyclohepta[4,5]benzo[1,2]cycloocten-6-one
|
|
3 | 2.629 |
| 41-865-6 |
5-«alpha»-Pregnan-3-«beta»,20-«alpha»,21-triol, TMS
|
|
3 | 8.937 |
| 42-134-6 |
1,2,3,4,6,7,8,9,10,11-Decahydro-5,11a-diaza-cycloocta[b]naphthalen-12-one
|
|
3 | 2.239 |
| 42-582-9 |
5«beta»-Androstan-3«alpha»,11«beta»-diol-17-one (Androsterone), MO-3-mono-TMS
|
|
3 | 5.222 |
| 42-635-0 |
5«beta»-Pregnane-3«beta»-ol-20-one, MO TMS
|
|
3 | 6.888 |
| 42-657-6 |
2,6-Pyridinedicarboxylic acid, di(1-methoxydec-4-yl) ester
|
|
3 | 6.926 |
| 42-702-5 |
2,6-Pyridinedicarboxylic acid, di(5-methoxy-3-methylpent-2-yl) ester
|
|
3 | 3.517 |
| 43-109-3 |
2,3-Diazabicyclo[2.2.2]octane,1,2,3,4-tetramethyl-,trans-
|
|
3 | 1.870 |
| 43-250-6 |
5,5'-Bis-benzylmercapto-[2,2'-azo-1,3,4-thiadiazol]
|
|
3 | 6.390 |
| 43-278-6 |
6-methyl-1,2,3,4,5,6-hexahydro-(7H)-cyclopentapyridine-7-one
|
|
3 | 1.407 |
| 43-416-2 |
3-[((1,1,3,3,5,5-Hexamethyl-5-[(3Z)-non-3-en-1-yloxy]trisiloxanyl)oxy)methyl]pyridine
|
|
3 | 6.280 |
| 43-471-1 |
4H-Pyrido[1,2-a]pyrimidin-4-one, 2,9-dimethyl
|
|
3 | 1.311 |
| 43-527-9 |
3«alpha»,4«beta»,12«alpha»-trihydroxy-5«beta»-cholanoic acid, methyl ester-trimethylsilyl-ether derivative
|
|
3 | 9.115 |
| 43-713-2 |
Methyl 5-«beta»-cholan-3-«alpha»-ol-12-one-24-oate, oxime, TMS
|
|
3 | 8.272 |
| 43-815-9 |
4-Quinolinol, 4-ethynyldecahydro-1,2-dimethyl-, (2«alpha»,4«alpha»,4a«alpha»,8a«beta»)-
|
16067-80-4 |
3 | 1.634 |
| 43-820-3 |
4-Quinolinol,1,4-diethyldecahydro-2-methyl-(2«alpha»,4«beta»,4a«alpha»,8a«beta»)
|
38463-61-5 |
3 | 2.800 |
| 43-838-4 |
4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro, 7-methyl
|
|
3 | 0.826 |
| 43-863-6 |
7.alpha.-hydroxy-3-oxo-4-cholestenoate, O-methyloxime, TMS (2)
|
|
3 | 9.218 |
| 43-987-9 |
N-(5-Methylisoxazol-3-yl)-N-(trifluoroacetyl)-2,2,2-trifluoroacetamide
|
|
3 | 1.967 |
| 44-136-2 |
1-(2-Chloro-3-(1-[(cyclohexylamino)carbonyl]-2-oxohydrazino)propyl)-1-[(cyclohexylamino)carbonyl]-2-oxohydrazine
|
33024-51-0 |
3 | 3.645 |
| 44-184-9 |
Silanamine, 1,1,1-trimethyl-N-[2-[4-[(trimethylsilyl)oxy]phenyl]ethyl]-
|
54965-31-0 |
3 | 3.867 |
| 44-200-0 |
N2-Cyclopropyl-1,3,5-triazine-2,4,6-triamine N6-acetyl
|
|
3 | -0.014 |
| 44-271-2 |
(E)-1-(4-Methylphenyl)butan-1-one O-(tert-butyldimethylsilyl)oxime
|
|
3 | 5.521 |
| 44-636-7 |
allo-Cholanic acid, 3«alpha»,7«beta»,12«beta»-trihydroxy, Me-DMES
|
|
3 | 10.285 |
| 44-732-0 |
O-Methyl-O-(1,1-difluoro-2-bromoethyl)-N-allyl-phosphorothioamidate
|
|
3 | 2.637 |
| 44-752-8 |
Pyrazolo[1,5-d][1,2,4]triazin-3-one, 2,5,6-trimethyl-7,7-pentamethylene
|
|
3 | 1.541 |
| 44-777-1 |
Disiloxane, 1,3-bis(bromomethyl)-1,1,3,3-tetramethyl-
|
2351-13-5 |
3 | 3.281 |
| 44-863-5 |
Silane, [(3.beta.,5.alpha.)-cholest-7-en-3-yloxy]trimethyl-
|
|
3 | 9.248 |
| 44-930-0 |
O-Methyl-O-(1,1-difluoro-2-bromoethyl)-N-isopropyl-phosphorothioamidate
|
|
3 | 2.860 |
| 45-191-0 |
O-Ethyl-O-isobutyl-S-(1,1-difluoro-3-ethylheptyl)-dithiophosphate
|
|
3 | 6.853 |
| 45-247-8 |
Silane, trimethyl[[(3«beta»,5«alpha»)-stigmastan-3-yl]oxy]-
|
55493-85-1 |
3 | 9.964 |
| 45-316-1 |
Ethyl ([1,1,3,3-tetramethyl-3-(pyridin-3-ylmethoxy)disiloxanyl]oxy)acetate
|
|
3 | 2.598 |
| 45-414-2 |
3«beta»,16«alpha»-dihydroxy-5«alpha»-androstan-17-one, TMS
|
|
3 | 6.648 |
| 45-429-6 |
5,5-Dimethyl-2-phenoxy-1,3,2-dioxaphosphorinane 2-sulphide
|
|
3 | 3.363 |
|
« Previous Results
Next Results »
|